Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 2183 • 2015 ACR/ARHP Annual Meeting
Clinical and Epidemiological Correlates of the Adjusted Global Anti-Phospholipid Syndrome Score in a Large Cohort of Chinese APS Patients
Yu Zuo¹, Chun Li², David R. Karp³ and Zhanguo Li², ¹Rheumatology, UT Southwestern Medical Center, Dallas, TX, ²Peking University People's Hospital, Beijing, China, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: It is well known that anti-phospholipid antibodies (aPL) are associated with an increased risk of arterial and venous thrombosis and pregnancy loss/morbidity. However, anticoagulation…
Abstract Number: 2184 • 2015 ACR/ARHP Annual Meeting
Non-Criteria Clinical Manifestations in Antiphospholipid Syndrome: Clinical Behavior and Association with Damage Accrual
Gabriela Hernandez-Molina¹, Cindy Maldonado-Garcia¹ and Antonio R. Cabral², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ²Immunology & Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico
Background/Purpose: The relevance of non-criteria clinical manifestations of antiphospholipid syndrome (APS) has been less studied than its thrombotic and obstetric features. The aim of this…
Abstract Number: 2186 • 2015 ACR/ARHP Annual Meeting
The Role of Hydroxychloroquine Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies
Savino Sciascia¹, Beverely J Hunt², Eva Talavera-Garcia³, Gloria Lliso³, Munther Khamashta³ and Mª Jose Cuadrado⁴, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Thrombosis & Haemostasis, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, London, United Kingdom, ³Louise Coote Lupus Unit, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
Background/Purpose: With good management, around 70% of pregnant women with Antiphospholipid Syndrome (APS) will deliver a viable live infant.However, current management does not prevent all…
Abstract Number: 2192 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Thrombocytopenia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
YU PEI CHOCK¹, DENIS WAHL² and STEPHANE ZUILY³, ¹KENT MEMORIAL HOSPITAL, WARWICK, RI, ²CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ³CHU de Nancy, Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Vascular Medicine Division, NANCY, France
Background/Purpose : Thrombocytopenia is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our objective was…
Abstract Number: 2195 • 2015 ACR/ARHP Annual Meeting
Long Term Outcome of Primary Antiphospholipid Syndrome Patients: A Multicenter Study
Francesca Dall'Ara¹, Mara Taraborelli², Rossella Reggia¹, Micaela Fredi², Maria Gerosa³, Laura Massaro⁴, Ariela Hoxha⁵, Marta Tonello⁵, Patrice Cacoub⁶, Nathalie Costedoat-Chalumeau⁷, Franco Franceschini², Pier Luigi Meroni⁸, Jean Charles Piette⁶, Amelia Ruffatti⁵, Guido Valesini⁴ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ³Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milano, Italy, ⁴Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, ⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ⁷Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁸Division of Rheumatology, Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy
Background/Purpose: Data on the long-term outcome in primary antiphospholipid syndrome (PAPS) patients (pt) are still very limited.The objectives of this work was to assess the…
Abstract Number: 2199 • 2015 ACR/ARHP Annual Meeting
in Vivo Ubiquinol Supplementation Reduces the Pro-Atherothrombotic Status in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial
Chary Lopez-Pedrera¹, Maria Ángeles Aguirre Zamorano¹, Francisco Velasco², Patricia Ruiz-Limon¹, Nuria Barbarroja¹, Yolanda Jiménez Gómez¹, Maria Carmen Abalos-Aguilera¹, Pedro Segui³, Eduardo Collantes-Estevez¹, Lucia Fernandez-del Rio⁴, Jose Antonio Gonzalez-Reyes⁴, Jose Manuel Villalba⁴, Mª Jose Cuadrado⁵ and Carlos Perez-Sanchez¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Hematology, IMIBIC-Reina Sofia Hospital, Hematology Unit, Cordoba, Spain, ³IMIBIC-Reina Sofia University Hospital, Radiology Unit, Cordoba, Spain, ⁴Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain, ⁵Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
Background/Purpose: To investigate the beneficial effects of in vivoubiquinol (Q, reduced form of CoQ10) supplementation on athero-thrombosis prevention in APS patients, through the implementation of…
Abstract Number: 2201 • 2015 ACR/ARHP Annual Meeting
Triple Positivity of Antiphospholipid Antibody As the Main Thrombotic Factor in a Long-Term Follow-up Study of 98 Asymptomatic Apl-Positive Carriers
Cécile Yelnik^1,2, Elodie Drumez³, Sylvain Dubucquoi^2,4,5, Vincent Sobanski^1,2,4, Hélène Maillard^1,6, Alain Duhamel³, David Launay^1,2,4, Eric Hachulla^1,2,4, Pierre-Yves Hatron^1,2 and Marc Lambert^1,2,4, ¹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ²Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ³CERIM, Université Lille Nord de France, Lille, France, ⁴LIRIC, INSERM UMR 995, Lille, France, ⁵Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, ⁶Faculté de Médecine Henri Warembourg, Université Lille Nord de France, lille, France
Background/Purpose: There is limited data regarding the long-term risk of developing a first-time thrombotic event and prophylactic benefits of aspirin use in asymptomatic aPL-positive carriers.…
Abstract Number: 2919 • 2015 ACR/ARHP Annual Meeting
Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis
Krishan Gupta¹, Manish Rathi², Navin Pattanashetti³, Ritambhra Nada⁴ and Aman Sharma⁵, ¹Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Internal Medicine, Junior Resident, Chandigarh, India, ⁴Histopathology, Professor, Chandigarh, India, ⁵Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: In addition to glomerular lesion, renal vascular lesion is also an important prognostic marker of lupus nephritis (LN). Among various vascular changes thrombotic microangiopathy…
Abstract Number: 1854 • 2015 ACR/ARHP Annual Meeting
Identification and Characterization of microRNAs Related to the Pathogenesis of Cardiovascular Disease in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Role of Specific Autoantibodies
Chary Lopez-Pedrera¹, Maria Ángeles Aguirre Zamorano¹, Patricia Ruiz-Limon¹, Nuria Barbarroja¹, Yolanda Jiménez Gómez¹, Eduardo Collantes-Estevez¹, Mª Jose Cuadrado², Rocio Gonzalez-Conejero³, Constantino Martinez³ and Carlos Perez-Sanchez¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³Regional Centre for Blood Donation, University of Murcia, Murcia, Spain
Background/Purpose: 1) To identify and characterize miRNAs related to the pathogenesis of CVD in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) patients; 2) To…
Abstract Number: 2945 • 2015 ACR/ARHP Annual Meeting
Diffuse Alveolar Hemorrhage in SLE: Risk Factors, Response to Therapy, and Survival
Nayef M. Kazzaz¹, Patrick S. Coit², Emily E. Lewis³, W Joseph McCune⁴, Amr H. Sawalha² and Jason S. Knight², ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI, ⁴Int Med/ Rheum, University of Michigan, Ann Arbor, MI
Background/Purpose: While diffuse alveolar hemorrhage (DAH) is recognized as a life-threatening complication of SLE, little is known about its risk factors and response to therapy. …
Abstract Number: 2000 • 2015 ACR/ARHP Annual Meeting
Immune Response Against Â Î²2GPI Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome
Pier Luigi Meroni^1,2, Marisa Benagiano³, Maria Gerosa⁴, Jacopo Romagnoli⁵, Michael Mahler⁶, Maria Orietta Borghi^7,8, Alessia Grassi⁹, Chiara Della Bella³, Giacomo Emmi³, Amedeo Amedei^3,10, Elena Silvestri³, Lorenzo Emmi¹¹, Domenico Prisco^9,10 and Mario Milco D'Elios^3,10, ¹Clinical Sciences and Community Heath, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ²Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy, ³Department of Experimental and Clinical Medicine, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁴Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milano, Italy, ⁵Department of Surgery, Department of Surgery, Catholic University of Rome, Rome, Italy, ⁶Inova Diagnostics, San Diego, CA, ⁷Department of Clinical Sciences and Community Health, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁸Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁹Department of Experimental and Clinical Medicine,, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁰Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, AOU Careggi, Florence, Italy, ¹¹Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic,, Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, AOU Careggi, Florence, Italy
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of arterial and venous thrombosis, and by recurrent abortions, in patients with persistent presence of autoantibodies…
Abstract Number: 3124 • 2015 ACR/ARHP Annual Meeting
Associations of Circulating Cell-Free Micro-RNA with Vasculopathy and Vascular Events in SLE Patients
Susan Due Kay¹, Anting L. Carlsen², Anne Voss¹, Mikael Kjær Poulsen³, Axel Cosmus Pyndt Diederichsen⁴ and Niels H. H. Heegaard⁵, ¹Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ²Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark, ³Department of Cardiology, Odense University Hospital, Odense C, Denmark, ⁴Department of Cardiology,, Odense University Hospital, Odense C, Denmark, ⁵Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark
Background/Purpose: MicroRNAs (miRNAs) are small noncoding RNAs that modulate protein translation and regulate numerous immunologic and inflammatory pathways. Certain miRNA profiles have been associated with…
Abstract Number: 2003 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Is Characterized By Endothelial Progenitor Dysfunction and a Type I Interferon Signature
Robert C. Grenn¹, Srilakshmi Yalavarthi², Paula L. Bockenstedt³ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI
Background/Purpose: Patients with primary antiphospholipid syndrome (APS) are at risk for endothelial dysfunction and accelerated atherosclerosis. In systemic lupus erythematosus (SLE), there is a well-established…
Abstract Number: 2005 • 2015 ACR/ARHP Annual Meeting
Circulating Mirnas As Potential Disease Biomarkers in Antiphospholipid Syndrome Patients
Carlos Perez-Sanchez¹, Mihaela Diana Ivanoiu¹, Maria Ángeles Aguirre Zamorano¹, Patricia Ruiz-Limon¹, Nuria Barbarroja¹, Yolanda Jiménez Gómez¹, Maria Carmen Abalos-Aguilera¹, Rocio Gonzalez-Conejero², Constantino Martinez², Eduardo Collantes-Estevez¹, Mª Jose Cuadrado³ and Chary Lopez-Pedrera¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Regional Centre for Blood Donation, University of Murcia, Murcia, Spain, ³Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
Background/Purpose: Epigenetic anomalies are emerging as striking pathogenic features of autoimmune disorders. MicroRNAs (miRNAs) are small non-coding RNAs with a key role in regulatory networks that…
Abstract Number: 2865 • 2014 ACR/ARHP Annual Meeting
The Cellular Effects of ANTI-Factor Xa Antibodies Isolated from Patients with Antiphospholipid Syndrome ARE Inhibited By Factorxa Inhibitors, Hydroxychloroquine and Fluvastatin
Bahar Artim-Esen¹, Natalia Smoktunowicz², Vera M. Ripoll³, Charis Pericleous⁴, Rachel Chambers², Ian Mackie⁵, David Isenberg⁶, Anisur Rahman⁷, Yiannis Ioannou⁶ and Ian Giles⁴, ¹Department of Internal Medicine, Division of Rheumatology, Rheumatology Division, Department of Internal Medicine, Istanbul Faculty of Medicine,Istanbul University, Istanbul, Turkey, ²Rayne Institute, 1st floor, Respiratory Research Unit, University College London, London, United Kingdom, ³Centre for Rheumatology, Rayne Institute, 4th floor, Centre for Rheumatology, University College London, London, United Kingdom, ⁴Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁵Haemostasis Research Unit, 1st Floor, 51 Chenies Mews, Haemostasis Research Unit, University College London, London, United Kingdom, ⁶Centre for Rheumatology Research, University College Hospital London, London, United Kingdom, ⁷Centre for Rheumatology Research, University College London, London, United Kingdom
Background/Purpose Recently we showed that FXa reactive IgG in patients with the antiphospholipid syndrome (APS) displayed higher avidity binding to FXa and had greater functional…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].